<p>Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <em>MYC</em>, <em>BCL2/BCL6</em> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study</p>

Qianwen Ma(Affiliated Hospital of Jiangsu University), Lei Zhang(First Affiliated Hospital of Zhengzhou University), Xi-Yang Liu(Xidian University), Yang Li(Apple (Israel)), Qian Zhao(Shanghai Open University), Lan Zhang(Lanzhou University Second Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li(China Medical University), Xinhua Wang(Zhengzhou University), Xudong Zhang(Southwest University of Science and Technology), Jingjing Wu(Beijing Tian Tan Hospital), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Hui Yu(First Affiliated Hospital of Zhengzhou University), Ling Li(Johns Hopkins University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Yu Chang(Jilin University), Zhi‐Yuan Zhou(Tsinghua University), Feifei Nan(First Affiliated Hospital of Zhengzhou University), Zhaoming Li(First Affiliated Hospital of Zhengzhou University)
Cancer Management and Research
February 1, 2019
Cited by 11


Related Papers